Company news

hVIVO plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

£7.3m Influenza human challenge study contract win

May 18, 2022

Wellcome publication

May 12, 2022

Vaccine field study contract

May 5, 2022

Challenge virus manufacturing contract

May 4, 2022

Appointment of Nominated Adviser and Joint Broker

April 28, 2022

Proposal to Distribution in Specie Shareholders

April 13, 2022

Characterisation Study results in Nature Medicine

March 31, 2022

£5m RSV human challenge study contract win

March 25, 2022

Trading Update and screening facilities expansion

March 8, 2022

Investor Presentations

March 2, 2022

CEO Appointment

February 24, 2022

FDA Breakthrough Designation for Big Pharma RSV

February 22, 2022

Positive results from RSV Human Challenge Study

February 17, 2022

Launch of STRiVE project

February 14, 2022

World's first COVID-19 Characterisation Study

February 2, 2022

Malaria Human Challenge Model Launched

January 20, 2022

£5m Influenza human challenge study contract win

December 21, 2021

$13.4m Influenza HCS contract win

December 10, 2021

Positive results from Flu Human Challenge Study

December 6, 2021

Imutex Vaccine Phase I Study Results

November 19, 2021

£5.1m RSV contract

November 17, 2021

£1.5m Contract renewal for Venn Life Sciences

November 15, 2021

Half-year Report

September 20, 2021

£8.1m Asthma Human Challenge Study Contract Win

August 24, 2021

Malaria Human Challenge Model

August 9, 2021

DNDi Phase II trial support

July 29, 2021

NEJM Opinion Piece

July 22, 2021

Directors' Dealings

July 14, 2021

HRV and Flu contract

July 9, 2021

2020 Annual Report and 2021 AGM Notice

June 30, 2021

Demerger Update

June 17, 2021

Re. Distribution in Specie and Notice of Results

June 14, 2021

Court Approval

May 19, 2021

Exercise of Share Options

May 10, 2021

Result of General Meeting

April 29, 2021

Potential demerger of certain non-core assets

April 13, 2021

Launch of Disease in Motion platform

April 9, 2021

£7.5m Human Challenge Study Contract

March 26, 2021

COVID-19 Human Challenge Programme update

March 25, 2021

Journal for Clinical Studies article publication

March 11, 2021

New contract win with Oxford BioTherapeutics

March 9, 2021

Ethics approval - COVID-19 Human Challenge Study

February 17, 2021

Exercise of Investor Warrants & TVR

February 3, 2021

Contract extension with Carna Biosciences

February 1, 2021

Article published in Drug Discovery Today

January 21, 2021

Expansion of volunteer recruitment centres

January 20, 2021

First volunteer dosed in COVID-19 clinical trial

January 11, 2021

Contract renewal with top-3 pharmaceutical client

January 6, 2021

Rule 19.6(c) Confirmation

December 31, 2020

Successful completion of toxicology study

December 23, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.